Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective.

Saved in:
Bibliographic Details
Title: Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective.
Authors: Torre E; Diabetology and Metabolic Diseases Unit, ASL3 Genoa, Genoa, Italy., Di Matteo S; Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy., Martinotti C; Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy., Bruno GM; Department of Drug Sciences, University of Pavia, Pavia, Italy., Cabrino A; Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy., Fogliati EL; Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy., Giusti A; Internal Medicine Unit, ASL3 Genoa, Genoa, Italy., Barbieri M; Otolaryngology Unit, ASL3 Genoa, Genoa, Italy., Bottaro LC; General Direction, ASL3 Genoa, Genoa, Italy., Colombo GL; Department of Drug Sciences, University of Pavia, Pavia, Italy.
Source: ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2026 May 01; Vol. 18, pp. 585328. Date of Electronic Publication: 2026 May 01 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101560564 Publication Model: eCollection Cited Medium: Print ISSN: 1178-6981 (Print) Linking ISSN: 11786981 NLM ISO Abbreviation: Clinicoecon Outcomes Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1178-6981
DOI:10.2147/CEOR.S585328